Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

When An SPA Is Not Enough: FDA Will Consider Response Rate For Allos Drug

Apr 06 2009

• By Jamie Hammon

Related Content

GSK Looks To Build On Supportive Care Presence With Promacta And Rezonic

Jun 25 2007

FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival

Jun 04 2007

Obesity Guidance Should Be More Lenient On Indications, Firms Tell FDA

Jun 18 2007

FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Jun 18 2007

Kweder Deposition Strengthens Link Between White House, Plan B – CRR

Jan 08 2007

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

Dec 10 2007

Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review

Feb 19 2007

Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets

Feb 02 2009

Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Feb 02 2009

Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential

Apr 06 2009

Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?

Apr 06 2009

Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint

Mar 30 2009

Arena Defends Obesity Drug After Phase III BLOOM Wilts

Mar 30 2009

Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal

Jan 19 2009

DeLauro Adds FDA Scientists’ Complaint To Her List Of Agency Problems

Jan 19 2009

Bristol Reports Strong 2008 Earnings But Sharp Patent Cliffs Loom

Jan 27 2009

Inverness Forced To Release Pregnancy Test Technology

Jan 05 2009

Congress’ Omnibus Language Seeks FDA Progress Reports On Spending

Mar 02 2009

Value Strategy Offers Alternative To Price Cuts For Some Firms

Mar 02 2009

BLA Exclusivity Would Ease Acquisitions And Improve R&D Focus, Lilly Says

Mar 02 2009

Teva’s Generic Evista Launch Remains On Hold During Patent Trial

Mar 10 2009

Congress Stresses Food Safety Responsibility For All Links In Supply Chain

Mar 23 2009

GSK Plans To Wield Aggressive Bolt-On Acquisition Strategy

Jan 26 2009

Orexigen Starts Partnership Talks On Obesity Drug Contrave

Jan 13 2009

The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement

Jan 01 2009

Brand/Generic Settlements Return To Capitol Hill

Mar 26 2009

After Combining Assets, Takeda/Millennium Outline Oncology Strategy

Mar 27 2009

Tobacco Oversight Looks More Likely, But Is It Bad For FDA’s Health?

Mar 09 2009

First Course For Waxman: Fix Food Safety, Hold The Separate Agency Plan

Mar 16 2009

Bush’s “Conscience” Rule Limiting Plan B Access On HHS Chopping Block

Mar 30 2009

HHS Public Health Pick Could Accelerate Tobacco, Sunscreen Oversight

Mar 30 2009

Plan B Ruling Sets A Precedent That Could Give FDA Pause

Mar 30 2009

Sharfstein Is Acting FDA Commissioner As Hamburg Awaits Confirmation

Mar 30 2009

Plan B Ruling: Little Commercial Impact, Big Policy Implications

Mar 30 2009

Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza

Mar 06 2009

“Snurf” Abuse Reports Revive Interest In DXM Bills

Sep 15 2008

HHS Price Negotiation Under Medicare Rx Would Not Beat PBM Prices – CMS

Feb 21 2005

Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma

Mar 16 2005

GSK Files NDA For Oncology Anti-Nausea Drug

May 30 2008

Debiopharm Takes Up Confirmatory Phase III Trial Of Sanvar

Jun 01 2006

Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget

Apr 30 2007

Analysts Hot, Investors Lukewarm On Allos’ Pralatrexate Phase II

Dec 08 2008

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Dec 22 2008

Tissue Samples Will Play Important Role In Identifying Predictive Biomarkers

Dec 22 2008

Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term

Dec 15 2008

PhRMA’s Revised DTC Code Shies Away From Internet; Not Celebrities

Dec 15 2008

Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes

Dec 15 2008

Tysabri For Crohn’s: Risk Management Is Same, But Could Be Higher Hurdle

Jan 21 2008

Prasugrel Intellectual Bias: FDA Makes Changes, Congress Demands Answers

Mar 09 2009

Diabetes Therapies Need Cardiovascular Safety Data For Approval, Panel Says

Jul 07 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window